Zdrowie i gospodarka · 03/08/2023
FDA Clears Path for K-TAB Extended-Release Tablets
The FDA has determined that K-TAB extended-release tablets, 10 milliequivalents and 20 milliequivalents, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for approval of abbreviated new drug applications for these formulations.